<section class="casebody" data-case-id="NOTALEPH001591_0074" data-firstpage="1069" data-lastpage="1069">
  <section class="head-matter">
    <p class="decisiondate" id="b395-6" data-blocks='[["BL_395.11",395,[557,875,330,43]]]'>OCTOBER 29, 1951</p>
    <h4 class="parties" id="b395-7" data-blocks='[["BL_395.12",395,[63,934,456,42]]]'>
      <em>In re Don Baxter, Inc.</em>
    </h4>
    <p class="docketnumber" id="ARa" data-blocks='[["BL_395.13",395,[548,933,214,44]]]'>(No. 5867).</p>
  </section>
  <article class="opinion" data-type="majority">
    <p id="AXL" data-blocks='[["BL_395.14",395,[806,933,580,44]],["BL_395.15",395,[104,984,680,43]]]'>Trade-mark for solutions for parenteral, enteral, and topical use.</p>
  </article>
</section>